HMG-CoA Reductase Inhibitor (Statin)
Pregnancy: X
Atorvastatin
Brand names: Lipitor
Adult dose
Dose: 10–80 mg once daily (usually 20–80 mg for high CV risk); 10–20 mg for primary prevention
Route: oral
Frequency: once daily
Max: 80 mg/day
Can be taken at any time (unlike some other statins); high-intensity statin therapy: 40–80 mg; no need to avoid grapefruit if moderate amounts
Paediatric dose
Route: oral
Frequency: once daily
Max: 20 mg/day (age 10–17)
Familial hypercholesterolaemia: ≥10 years: 10 mg once daily, titrate to max 20 mg; specialist initiation
Dose adjustments
Renal
No dose adjustment required
Hepatic
Contraindicated in active liver disease or unexplained persistent elevated LFTs
Clinical pearls
- ASCOT-LLA trial: 36% reduction in MI in hypertensive patients with total cholesterol <6.5 mmol/L
- High-intensity statin: ≥40% LDL reduction; 80 mg atorvastatin — most potent available in UK
- CK should be checked before starting if high myopathy risk (elderly, renal impairment, high-dose, drug interactions)
Contraindications
- Active liver disease
- Pregnancy
- Breastfeeding
- Concurrent potent CYP3A4 inhibitors (ciclosporin — use pravastatin instead)
Side effects
- Myalgia
- CK elevation
- Rhabdomyolysis (rare)
- Elevated LFTs
- Headache
- GI upset
- Diabetes mellitus (modest risk)
Interactions
- Ciclosporin (CI — markedly increases levels)
- Fibrates (especially gemfibrozil — myopathy)
- Macrolides/azoles (increase levels)
- Amiodarone (max 20 mg atorvastatin)
Monitoring
- LFTs (baseline, 3 months, and 12 months)
- CK (if myopathy symptoms)
- Lipid profile (3 months after initiation)
Reference: BNFc; BNF 86; NICE NG238; ASCOT-LLA trial. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- Framingham Risk Score · Cardiovascular Risk
- ACC/AHA Pooled Cohort Equations — ASCVD Risk · Cardiovascular Risk
- PREVENT Cardiovascular Risk Calculator (AHA/ACC 2023) · Cardiovascular Risk
- Reynolds Risk Score for Women · Cardiovascular Risk
- SCORE2 — 10-Year CVD Risk (Age 40–69) · Cardiovascular Risk
- SCORE2-OP — 5/10-Year CVD Risk (Age ≥ 70) · Cardiovascular Risk
Pathways
- Peripheral Arterial Disease · NICE NG19 2012 / ESVS 2017
- Carotid Artery Disease · NICE CG68 / ESVS 2018
- Varicose Veins Management · NICE CG168 2013
- Venous Leg Ulcer Management · NICE NG204 2022
- Acute Heart Failure · ESC 2021 Heart Failure Guidelines; NICE NG106
- NSTEMI / Unstable Angina · ESC 2020 NSTEMI Guidelines; NICE NG185